Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Immatics N.V.

Market Cap 130.11Cr 113.52Cr 104.64Cr 99Cr 183.89Cr 12TCr 185.42Cr 1.25TCr 482.82Cr 6.04TCr 488.34Cr 477.85Cr 21TCr P/E 2026 *
-4.77x
P/E 2027 * -5.2x
Enterprise Value 100.86Cr 88Cr 81Cr 76Cr 142.54Cr 9.51TCr 143.73Cr 965.7Cr 374.25Cr 4.68TCr 378.53Cr 370.4Cr 16TCr EV / Sales 2026 *
22x
EV / Sales 2027 * 18.9x
Free-Float
74.82%
Yield 2026 *
-
Yield 2027 * -
1 day+2.73%
1 week+10.26%
Current month-15.03%
1 month-10.03%
3 months-0.51%
6 months-1.41%
Current year-6.86%
1 week 9
Extreme 9
9.98
1 month 8.76
Extreme 8.76
11.86
Current year 8.55
Extreme 8.55
11.94
1 year 5.05
Extreme 5.05
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
16.3
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Date Insider Type Main position Quantity % Market Cap.
18/03
Perceptive Advisors LLC
OtherCompany 1,05,54,956 7.8731%
18/03Other

Chairman

4,89,461 0.3651%
18/03Other

Executive/Senior Manager

10,64,420 0.7940%
Change 5-day change 1-year change 3-year change Capi.($)
+2.73%+10.26%+59.28%-23.11% 130.11Cr
-2.23%-0.03%+61.34%+109.10% 5.62TCr
+4.60%+5.85%+54.47%+43.04% 4.38TCr
-1.44%+5.50%-13.41%-19.24% 2.33TCr
-2.69%+4.27%-4.47%+379.00% 2.13TCr
+3.22%+3.77%+19.92%-35.05% 1.58TCr
-0.67%+1.18%+12.91%-39.22% 1.56TCr
-1.01%-1.27%+25.52%+171.92% 1.32TCr
+3.07%+3.59%+25.54% - 1.2TCr
+4.95%+7.51%+123.21%+249.05% 1.19TCr
Average +1.05%+4.11%+36.43%+92.83% 2.14TCr
Weighted average by Cap. +0.52%+3.57%+37.89%+97.29%

Financials

2026 *2027 *
Net sales 4.59Cr 4.01Cr 3.69Cr 3.48Cr 6.49Cr 433.05Cr 6.54Cr 44Cr 17Cr 213.08Cr 17Cr 17Cr 740.49Cr 5.06Cr 4.42Cr 4.07Cr 3.83Cr 7.16Cr 477.51Cr 7.21Cr 48Cr 19Cr 234.96Cr 19Cr 19Cr 816.53Cr
Net income -28Cr -24Cr -22Cr -21Cr -39Cr -2.63TCr -40Cr -266.99Cr -103.47Cr -1.29TCr -104.65Cr -102.41Cr -4.5TCr -28Cr -25Cr -23Cr -21Cr -40Cr -2.65TCr -40Cr -269.31Cr -104.37Cr -1.31TCr -105.56Cr -103.29Cr -4.54TCr
Net Debt -29Cr -26Cr -24Cr -22Cr -41Cr -2.76TCr -42Cr -280.15Cr -108.57Cr -1.36TCr -109.81Cr -107.45Cr -4.72TCr -35Cr -30Cr -28Cr -26Cr -49Cr -3.26TCr -49Cr -331.28Cr -128.38Cr -1.61TCr -129.85Cr -127.06Cr -5.58TCr
Logo Immatics N.V.
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Employees
678
Date Price Change Volume
18/26/18 9.770 $ +2.63% 4,14,323
17/26/17 9.520 $ +4.73% 2,92,980
16/26/16 9.090 $ -3.61% 2,08,616
15/26/15 9.430 $ +0.53% 1,63,453
12/26/12 9.380 $ +3.53% 3,76,663
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.770USD
Average target price
18.78USD
Spread / Average Target
+92.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!